Clinical Trial

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

Study acronym: ePRO-LC-CRT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.
Trial Details
NCT Number NCT07131670
Lead Sponsor Qian Chu
Conditions Lung Cancer, Chemoradiotherapy, Patient-Reported Outcomes (PRO)
Enrollment 100 participants
Start Date 2024-06-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-20